AI in Neurological Clinical Trials: Strategic Insights from John E. Kelly III, PhD
AI pioneer Dr. John E. Kelly III shares insights on building trust, improving data, and driving progress in AI-enabled neurological trials.
AI pioneer Dr. John E. Kelly III shares insights on building trust, improving data, and driving progress in AI-enabled neurological trials.
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Over 750 industry clinical trials have been initiated for...
The imaging clinical trials industry continues to grow in the face of unique challenges! To help you keep up, we’ve put together the top trends to...
Discover how AI enhances medical imaging workflows, boosting accuracy and efficiency. Learn benefits, challenges, and how QMENTA simplifies AI...
Take a look ahead at our predicted trends for neuroscience in 2025 - where technology, neuroplasticity, and neuroethics are reshaping the way we...
Discover insights into structural and functional aspects of the human brain, potential biomarkers, and applications in psychiatric research.
Discover Hybrid Cloud Imaging on QMENTA: merging automated & manual processes for peak accuracy in medical imaging.
Unleashing automated white matter lesion segmentation: Advancements in MS assessment. Evolving imaging techniques, revolutionizing diagnosis &...